Aptamer Therapeutics for Complement Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic and diagnostic options for complement-related disorders, such as those involving the C5 protein, face limitations due to the immunogenicity and administration challenges of antibody-based treatments.
Innovation Solution
Development of aptamers, specifically nucleic acid molecules with high specificity and affinity for the C5 protein, which are chemically synthesized, stable, and can be administered subcutaneously, offering improved pharmacokinetic properties and reduced immunogenicity compared to traditional antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based treatments are used for complement-related disorders, then therapeutic efficacy is achieved, but immunogenicity and administration challenges occur
Solution Approach 1:
The patent uses aptamers as simplified copies or analogs of monoclonal antibodies. Instead of using full antibody molecules with complex protein structures that trigger immune responses, the invention employs smaller nucleic acid molecules (aptamers) that replicate the target-binding function of antibodies without their immunogenic properties. The aptamers are selected to bind complement proteins with high affinity, mimicking antibody therapy while avoiding immune reactions to the therapeutic agent itself.
2Measurement precision
If monoclonal antibodies are used, then specific binding to C5 protein is achieved, but administration complexity and cost increase
Solution Approach 1:
The patent employs aptamers that are chemically synthesized rather than produced through complex biologic manufacturing processes required for monoclonal antibodies. This chemical synthesis approach dramatically reduces production complexity and cost. The aptamers are designed to be stable enough for therapeutic use but can be produced through relatively simple chemical processes, making them more accessible and easier to administer compared to complex antibody therapies.
3Object-affected harmful factors
If aptamers are used instead of antibodies, then immunogenicity is reduced, but binding affinity and stability must be maintained
Solution Approach 1:
The patent utilizes extensive chemical modifications of the aptamer backbone to optimize both stability and binding properties. Various sugar modifications (2'-O-methyl, 2'-fluoro, locked nucleic acids), phosphate backbone modifications (phosphorothioates), and base modifications are employed to enhance nuclease resistance, improve thermal stability, and maintain or enhance binding affinity to complement proteins. These parameter changes allow the aptamers to achieve the necessary pharmacokinetic properties for therapeutic use while maintaining low immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Aptamers effectively inhibit C5-mediated processes, providing therapeutic and diagnostic benefits with enhanced stability, scalability, and cost-effectiveness, while minimizing immune response and improving delivery efficiency.
Implementation Method 1
Aptamers are nucleic acid molecules having specific binding affinity to molecules through interactions other than classic Watson-Crick base pairing
Data Source
AI summary
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.